Palvella Therapeutics (PVLA) grants CFO 44,123 stock options

Rhea-AI Filing Summary

Palvella Therapeutics, Inc. reported that CFO and Treasurer Matthew E. Korenberg received a grant of stock options for 44,123 shares of common stock on February 5, 2026. The options carry an exercise price of $76.43 per share and expire on February 5, 2036.

The options vest in equal monthly installments over 48 months starting February 5, 2026, as long as he remains in continuous service through each vesting date. Following this award, he beneficially holds 44,123 derivative securities directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Korenberg Matthew E

(Last) (First) (Middle)

C/O PALVELLA THERAPEUTICS, INC.

353 W. LANCASTER AVENUE, SUITE 200

(Street)

WAYNE PA 19087

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PALVELLA THERAPEUTICS, INC. [ PVLA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO, Treasurer

3. Date of Earliest Transaction (Month/Day/Year)
02/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$76.43	02/05/2026		A		44,123		(1)	02/05/2036	Common Stock	44,123	$0	44,123	D

Explanation of Responses:

1. The shares subject to this option shall vest and become exercisable in equal monthly installments over 48 months commencing from February 5, 2026, subject to the Reporting Person's continuous service through each applicable vesting date.

	/s/ Kathleen A. McGowan, Attorney-in-Fact	02/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did PVLA report for CFO Matthew Korenberg?

Palvella Therapeutics (PVLA) reported that CFO and Treasurer Matthew E. Korenberg received a grant of 44,123 stock options on February 5, 2026. These options relate to common stock and were reported as a direct ownership position following the grant.

What are the key terms of the 44,123 stock options granted by PVLA?

The grant consists of 44,123 stock options with an exercise price of $76.43 per share, expiring on February 5, 2036. These options give the right to buy Palvella common stock at that price during the option term.

How do Matthew Korenberg’s PVLA options vest over time?

The options vest in equal monthly installments over 48 months, beginning on February 5, 2026. Vesting is conditioned on Mr. Korenberg’s continuous service with Palvella Therapeutics through each applicable monthly vesting date.

How many Palvella derivative securities does the CFO hold after this Form 4?

After the transaction, Matthew E. Korenberg beneficially owns 44,123 derivative securities, all held directly. These represent stock options tied to Palvella common stock, reflecting only this reported grant in the filing’s ownership total.

Was the PVLA CFO’s stock option transaction a purchase or a grant?

The Form 4 shows transaction code “A”, indicating an award or grant of derivative securities. The options were granted at an exercise price of $76.43 per share, with a reported transaction price of $0.00 for the award itself.